Breakthrough in Malaria Treatment for Infants Promises Progress Towards Eradicating the Disease in Africa

In July 2025, Swissmedic approved the first dedicated malaria treatment specifically formulated for infants aged 2 months to 5 years, marking a significant milestone in the fight against malaria in Africa. Previously, young children received medications designed for older children, which posed risks of adverse effects due to differences in physiology. This new medication, called Coartem Baby, is a tailored treatment that caters to the unique needs of the most vulnerable, including those as small as 4.5 kilograms.

The approval comes as part of a collaborative effort involving Novartis, Medicines for Malaria Venture, and the Swiss Agency, with support from initiatives like the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. The drug has already been rolled out in Ghana, with plans to introduce it in other countries such as Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda.

This development represents a crucial step towards the global goal set by the World Health Organization (WHO) to eradicate malaria by 2030. Effective and age-appropriate treatments for the youngest children can save countless lives and significantly reduce the disease's burden in Africa. Experts highlight that this innovation not only saves lives but also inspires local scientists and the broader African research ecosystem to continue advancing malaria research and vaccine development.

Malaria remains a severe health challenge in Africa, accounting for approximately 94% of cases and 95% of deaths worldwide in 2023, with children under five bearing the heaviest burden. The lack of suitable treatments has historically hindered efforts to protect these vulnerable populations. The introduction of targeted therapies like Coartem Baby could revolutionize neonatal malaria care and help close the treatment gap.

However, the rollout faces hurdles, such as ensuring sufficient funding, establishing local manufacturing capabilities, and adapting formulations for challenging environments like areas with power shortages. Strategic investments and collaborations are essential to make this life-saving medication accessible across the continent.

Overall, this milestone signifies hope for a future where malaria can be effectively controlled and eventually eradicated in Africa. By focusing on the health of the youngest, the continent moves closer to unlocking its full potential, improving health outcomes, and fostering economic growth through a healthier population.

[source: https://medicalxpress.com/news/2025-07-malaria-treatment-babies-major-disease.html]